Navigation Links
Mount Sinai researchers develop first successful laboratory model for studying hepatitis C
Date:8/2/2013

By differentiating monkey stem cells into liver cells and inducing successful infection, researchers from the Icahn School of Medicine at Mount Sinai have shown for the first time that the hepatitis C virus (HCV) can replicate in monkeys, according to research published in the journal Gastroenterology. The new findings may lead to the first new animal model and provide new avenues for developing treatments and vaccines for this disease, which impacts more than three million people in the United States.

Scientists have tried for decades to develop animal models to study HCV, but the virus was incapable of infecting any species except for humans and chimpanzees. With a recent National Institutes of Health-imposed moratorium restricting chimpanzee research, the Mount Sinai research team turned to a close relative of chimpanzees and humansmacaques. Led by Matthew Evans, PhD, and Valerie Gouon-Evans, PhD, of Mount Sinai, the research team sought to find out why previous attempts to infect macaques with HCV failed.

Dr. Gouon-Evans, who is Assistant Professor of in the Department of Developmental and Regenerative Biology at Mount Sinai, worked with a team at the Fred Hutchison Cancer Research Center in Seattle to differentiate macaque stem cells into liver cells. Dr. Evans, who is an Assistant Professor in the Department of Microbiology, and his team then attempted to infect these cells with HCV in a petri dish. They found that these differentiated cells were able to support HCV infection and replication, although not as effectively as in human liver cells.

"Now that we know that HCV infection in macaque cells is possible, we wanted to find out why it only worked in liver cells that were derived from stem cells," said Dr. Gouon-Evans. "By identifying where in the viral life cycle the infection is dysfunctional, we can develop an effective animal model of HCV."

Dr. Evans and his team found that HCV was less efficient at entering macaque cells to initiate infection compared to human cells because changes in the macaque form of a certain cell surface receptor rendered it less functional than the human version. This cell entry block could be overcome by expressing the human version of this receptor in macaque cells. Furthermore, HCV infection of normal macaque cells was greatly enhanced by changes to the virus that loosened its requirements for that receptor.

"Our discovery shows that by manipulating either host or viral genetics we can efficiently infect macaque cells," said Dr. Evans. "These findings may open doors for the field of HCV research, lead to new animal models, and hopefully vaccines and therapies."

Next, Dr. Evans plans to take these experiments out of petri dishes by attempting to infect macaques in vivo with the mutant HCV that can use the receptors this animal naturally expresses. If successful, this work would provide a new, much-needed animal model for HCV studies and vaccine development.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. AMP concerned about the structure and application of gap fill payment amounts
2. Total amount of exercise important, not frequency, research shows
3. Earthquake swarms; marine Ediacaran fossil traces; Alca obsidian; Mammoth Mountain
4. Mount Sinai celebrates team science at second-annual SINAInnovations Conference Nov. 18-19, 2013
5. Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration
6. Going green: Nation equipped to grow serious amounts of pond scum for fuel
7. Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
8. Mount Sinai Selects Exemplar LIMS for Genomics Core Facility
9. The right amount of vitamin D for babies
10. Mount Sinai study identifies new gene variations associated with heart rate
11. Mount Sinai leads global program using stem cells to accelerate cures for Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, Inc. ... on its oral peptide drug candidates, PTG-100 and ... the European Crohn,s and Colitis Organization (ECCO).  The ... Barcelona, Spain from February 15 – ... preclinical data on Protagonist drug candidates PTG-100 and ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology: